Abstract: The present invention relates to a polypeptide comprising a modified von Willebrand Factor (VWF) having a higher Factor VIII binding affinity than non-modified VWF, its pharmaceutical use and method of its preparation.

Abstract: A collagen material having a form of thin fibrils generally free of fibril-bundling proteogylcan interactions, and a method for providing the thin fibril collagen material from native collagen fibers. The method uses proteoglycan antibodies to disassociate the proteoglycan interactions in bundled collagen fibrils to provide the constituent fibrils. The process can be used as a model for arthritis and the resulting fibrils can be used to form new extracellular matrix biomaterials and new tissues.

Abstract: The present invention relates to a method for purifying lactoferrin, which is a pharmacologically important milk protein having various physiological activities, from a secretory fluid containing lactoferrin.

Abstract: Antibodies that bind with high affinity to swine H1N1 virus are described. In vivo experiments showed that one such antibody is able to fully protect mice challenged with a lethal dose of swine H1N1 virus. The antibody is also able to cure mice in a therapeutic setting when treated as late as up to 60 hours (2.5 days) after infection with swine H1N1 virus. Also described are recombinant forms of this antibody.

Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

Abstract: The invention provides proteins and compositions for the treatment and prevention of Streptococcus agalactiae (Group B streptococcus; GBS).

Abstract: Described herein is secretory IgA isolated from the intestinal luminal fluid and intestinal mucosal of animals such as pigs and cows. Also included are methods of isolating secretory IgA. The secretory IgA is useful in food compositions such as animal and human food compositions as well as pharmaceutical compositions to increase growth rate, improve feed efficiency, reduce gastrointestinal inflammation, reduce a risk of gastrointestinal infection in the animal, or a combination thereof.

Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.

Abstract: Isolated SAA peptides, fusion proteins and compositions comprising such are provided as are domain-specific SAA antibodies. Methods of treating sepsis and endotoxemia are also provided.

Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.

Abstract: The present invention is directed to a cross-reactive antibody, which specifically inhibits or blocks the mammalian Toll-like receptor 2 (TLR2)-mediated immune cell activation. The invention is further directed to an isolated nucleic acid or vector coding for the variable regions of the heavy and/or light chain of the antibody. It is further providing a pharmaceutical composition comprising the antibody, nucleic acid or vector and is directed to the use of the composition in the prevention and/or treatment of inflammatory processes or any other process induced by bacterial infection, trauma, or chronic inflammation, or for the prevention and/or treatment of bacteriaemia or sepsis.

Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.

Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract: The present invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in inducing cell death and/or inhibiting the growth and/or proliferation of pathological stem cells and/or progenitor cells associated with a neoplastic hematologic disorder, wherein the cells express IL1RAP. A related aspect of the invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in detecting pathological stem cells and/or progenitor cells associated with a neoplastic hematologic disorder, wherein the cells express IL1RAP. Further provided are pharmacological compositions comprising the agents of the invention and methods of using the same.

Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Abstract: The present invention relates to monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II) and their use for treating and diagnosing cancer diseases, such as ovarian cancers.

Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: Compositions and methods for inducing cell membrane wounding, cell permeabilization and cell killing are provided. The composition comprises a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell. Preferably, the cell surface antigen is associated with the cytoskeleton of the cell. A preferred polyvalent agent is an IgM, and enhanced cell wounding and killing can be provided by the addition of a crosslinking agent. At sublethal concentrations in vivo, the cell wounding antibodies permeabilize cells and dramatically enhance response to chemotherapeutic agents, even in patients refractory to the chemotherapeutic agents.

Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

Abstract: A method of preparing an epitope for a secondary antibody detected protein tag, comprising: constructing a expressing vector, comprising a nucleotide sequence for encoding the secondary antibody detected protein tag comprising at least one epitope selected from at least one primary antibody which is detected by corresponding secondary antibody; expressing the vector in a host cell; and obtaining the secondary antibody detected protein tag which is expressed in the host cell. Further, a method for constructing a protein molecular weight marker ladder, comprising constructing a plurality of recombinant protein tags with different molecular weights, wherein each the recombinant protein tag comprises at least one epitope of primary antibody. Besides, a secondary antibody detected protein tag comprises at least two peptide sequences of epitopes selected from primary antibodies of at least two different species.

Abstract: Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scDVD and scDVDFab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display).

Abstract: Provided herein are tandem Fcs and tandem Fc antibodies (“TFcAs”), e.g., tandem Fc bispecific antibodies (“TFcBAs”), which comprise one or at least two binding sites that specifically bind to one or more cell surface receptors. The binding sites are connected through a TFc, which TFc comprises a first Fc region and a second Fc region, wherein the first and the second Fc regions are linked through a TFc linker to form a contiguous polypeptide and dimerize to form an Fc dimer. Exemplary TFcBAs bind to the cell surface receptors c-Met and EpCam and inhibit signal transduction through the cell surface receptor(s) for which the binding sites of the TFcBA are specific.

Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.

Abstract: Digestion of cellulosic biomass solids can be enhanced in the presence of a phenolic solvent. Methods for digesting cellulosic biomass solids can comprise providing cellulosic biomass solids containing up to about 50% water by mass in a digestion medium comprising about 50% or more of an organic solvent by volume; heating the cellulosic biomass solids and the digestion medium in a digestion unit in the presence of molecular hydrogen and a slurry catalyst capable of activating molecular hydrogen, thereby forming an alcoholic component derived from the cellulosic biomass solids and liberating lignin therefrom; wherein the digestion medium and the water form a biphasic mixture in which the alcoholic component, slurry catalyst, and lignin are contained; removing at least a portion of the biphasic mixture from the digestion unit; converting at least a portion of the lignin into a phenolic solvent; and returning the phenolic solvent to the digestion unit.

Abstract: The present invention relates to cellulose mixed esters, processes for preparing these and uses of the cellulose mixed esters, for example in coating compositions. The cellulose mixed esters have glass transition temperatures that fall within an appropriate range to allow for film formation to occur at ambient temperatures and have a total degree of substitution per anhydroglucose unit of about 2.5 to about 3.5; a residual hydroxyl functionality per anhydroglucose unit of 0 to about 0.5; a degree of substitution per anhydroglucose unit by C2-C6 ester groups of about 0.5 to about 2.8; and a degree of substitution per anhydroglucose unit by Ievulinyl ester groups of about 0.2 to about 2.6.

Abstract: Provided is a cationic group-containing cellulose ether which, when incorporated in a hair wash, is able to give an excellent smoothness property and its sustained feeling, finger combability and coated feeling in rinsing, and which, when incorporated in a skin cleanser, is able to give an excellent moist feeling to the skin after washing, and also provided are a surfactant composition, a hair wash composition, a skin cleanser composition, a hair conditioner composition and a hair treatment composition containing the cationic group-containing cellulose ether.

Abstract: A cellulose resin produced by binding a hydrogenated cardanol containing 3-pentadecylcyclohexanol, and cellulose or a derivative thereof through the reaction between a hydroxy group of the hydrogenated cardanol, a hydroxy group of the cellulose or a derivative thereof and isocyanate groups of a diisocyanate compound.

Abstract: A lipophilic starch is provided along with methods of making the same. The starch is prepared by modifying the starch with an organic acid anhydride reagent, such as octenyl succinic anhydride, drying the modified starch to a moisture content of less than 15% by weight, and then heat treating the dried starch at a temperature of at least 100° C. for at least one minute.

Abstract: Modified macromolecular compounds obtainable by using specific amino silane polymerization initiator compounds and optionally chain end-modifying compounds are described. Polymer compositions including such modified macromolecular compounds and the use of such compositions in the preparation of vulcanized (crosslinked) elastomeric polymer compositions and articles are described.

Abstract: This invention relates to novel bridged a hafnium transition metal metallocene catalyst compounds having two indenyl ligands substituted at the 4 positions with a C1 to C10 alkyl, where the 3 positions are hydrogen (assuming the bridge position is counted as the one position) and the bridging atom is carbon or silicon which is incorporated into a cyclic group comprising 3, 4, 5, or 6 silicon and/or carbon atoms that make up the cyclic ring.

Abstract: The present invention is aimed to provide a highly-productive method for producing a stabilized fluoropolymer. The present invention relates to a method for producing a stabilized fluoropolymer, comprising the step of bringing a fluoropolymer to be treated into contact with a fluorinating agent to produce a stabilized fluoropolymer, while maintaining the concentration of hydrogen fluoride present in a reaction vessel at not higher than 1.0% by volume.

Abstract: Compounds and polymers obtained from such compounds are provided, wherein the compounds have (a) at least two polymerizable moieties, (b) at least one amino acid residue of an amino acid comprising at least two amine groups of which at least two amine groups have formed a carbamate, a thiocarbamate or a carbamide group, and (c) a biomolecular moiety linked directly or via a spacer to the carboxylic acid moiety of the diamino acid residue or a carboxylic acid to which such moiety can be linked.

Abstract: There is provided a process for producing an olefin polymer that is capable of producing an olefin polymer having high heat resistance and high molecular weight with excellent catalytic activity. The process for producing an olefin polymer includes a step of polymerizing at least one olefin selected from ethylene and ?-olefins having 4 to 30 carbon atoms in the presence of an olefin polymerization catalyst containing a transition metal compound represented by the general formula [I], the olefin polymer including constituent units derived from ethylene and ?-olefins having 4 to 30 carbon atoms in a total amount between more than 50 mol % and not more than 100 mol %, [in the formula [I], R1, R3 and R5 to R16 are each independently a hydrogen atom, a hydrocarbon group or the like; R2 is a hydrocarbon group or the like; R4 is a hydrogen atom; M is a transition metal of Group IV; Q is a halogen atom or the like; and j is an integer of 1 to 4].

Abstract: The present invention relates to a process for the preparation of catalytic support and the supported bimetallic catalysts, used in the production of ethylene homopolymers and ethylene copolymers with ?-olefins, of high and ultra high molecular weight with broad molecular weight distribution, in gas or liquid phase polymerization processes, the latter being in slurry, bulk or suspension, and the products obtained from these processes.

Abstract: Process for treating polyolefin particles obtained by gas-phase polymerization of one or more olefins in the presence of a polymerization catalyst system and a C3-C5 alkane as polymerization diluent in a gas-phase polymerization reactor, the process comprising the steps of a) discharging the polyolefin particles continuously or discontinuously from the gas-phase polymerization reactor and transferring the particles to a first degassing vessel; b) contacting therein the polyolefin particles with a gaseous stream comprising at least 85 mol-% of C3-C5 alkane while the polyolefin particles have an average residence time in the first degassing vessel of from 5 minutes to 5 hours; c) transferring the polyolefin particles to a second degassing vessel; d) contacting therein the polyolefin particles with a stream comprising nitrogen and steam while the polyolefin particles have an average residence time in the second degassing vessel of from 5 minutes to 2 hours, wherein the contacting is carried out at conditions un

Abstract: This invention relates to a process to produce propylene polymer using a bridged hafnium transition metal metallocene catalyst compounds having two indenyl ligands substituted at the 4 positions with a C1 to C10 alkyl, where the 3 positions are hydrogen (assuming the bridge position is counted as the one position) and the bridging atom is carbon or silicon which is incorporated into a cyclic group comprising 3, 4, 5, or 6 silicon and/or carbon atoms that make up the cyclic ring, where the propylene polymer has 1) greater than 40% vinyl chain ends, relative to the total unsaturated chain ends, 2) a Tm of 70° C. or more; an Mw of 3000 to 300,000 g/mol, and 4) a g?vis of 0.90 or less.

Abstract: [Object] To provide transition metal compounds with excellent catalytic activity which can afford olefin polymers such as propylene polymers that have high stereoregularity and high molecular weight and may be easily crystallized into a ?-phase. [Solution] The transition metal compound is represented by General Formula [I] or is enantiomer thereof: [in Formula [I], R1, R3, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15 and R16 are each independently a hydrogen atom, a hydrocarbon group, a heteroatom-containing hydrocarbon group, or a silicon-containing group; R2 is a hydrocarbon group, a hetero atom-containing hydrocarbon group, or a silicon-containing group; R4 is a hydrogen atom; any two substituents of the substituents R1 to R16 except R4 may be bonded to each other to form a ring; M is a Group IV transition metal; Q is a structure such as a halogen atom; and j is an integer of 1 to 4].

Abstract: Preparation of isobutene homopolymers or copolymers having a number average molecular weight of from 500 to 5 000 000 by polymerization of isobutene or an isobutene-comprising monomer mixture in the presence of a Lewis acid or a complex comprising a Lewis acid as polymerization catalyst, wherein the polymerization is carried out in the presence of at least one hemiacetal or full acetal which can be obtained by protic acid-catalyzed reaction of at least one C1-C12-hydrocarbyl alcohol with at least one aldehyde or ketone having from 1 to 12 carbon atoms.

Abstract: This invention relates to poly(acrylonitrile) homo- or co-polymer having a number average molecular weight (Mn) of at least 200,000 g/mol and a dispersity () of less than 1.3.

Abstract: The present invention provides a barrier laminate with enhanced heat resistance performance, comprising at least one organic layer and at least one inorganic barrier layer, the organic layer being formed by curing a polymerizable composition comprising a polymerizable compound having two or more polymerizable groups, and the total quantity of uncured component in the organic layer being 1.5 weight % or less of the total weight of the organic layer, and a novel polymerizable compound that can preferably used as the polymerizable compound, which is denoted by general formula (11): in general formula (11), R21 denotes hydrogen atom or methyl group; R22 denotes methyl group or cyclohexyl group; n denotes an integer of 0 to 2; and each instance of X denotes a group comprising a polymerizable group.

Abstract: A terminal-modified polymer is manufactured by performing a polymerization reaction of a vinyl aromatic monomer, a conjugated diene monomer or both in the presence of an anionic polymerization initiator: and then adding an alkoxy aluminum compound thereinto to terminate the polymerization reaction. Alternatively, a terminal-modified polymer can also be manufactured by adding an aluminum halide compound instead of the alkoxy aluminum compound to terminate the polymerization reaction, and allowing for a reaction with a lower alcohol having 1 to 4 carbon atoms. The resulting terminal-modified polymer can improve the dispersibility of silica used as a compounding agent in rubber compositions for automobile pneumatic tires and the like.

Abstract: The invention relates to a high pressure polymerisation process for the preparation of the polyethylene wherein the polymerisation process takes place in the presence of a cobalt containing complex. The cobalt containing complex may be a complex according to Formula (I): Formula (I) wherein y1, y2, y3 and y4 may, independently of one another be the same or different, H, (C1C20) alkyl, (C5-C20) cycloalkyl, (C6-C10) aryl radical, phenyl or hydroxy-phenyl.

Abstract: It is an object of the present invention to provide a chlorinated polyolefin resin having favorable adhesion to a polyolefin resin and high solubility in a composition containing an alcohol-based solvent. The present invention provides a chlorinated polyolefin resin that exhibits, in infrared spectroscopy spectrum measurement, a peak area ratio A/B×100 of 10% or higher, a peak area ratio C/B×100 of 30 to 80%, and a peak area ratio A/C×100 of 30% or higher (wherein “A” is the area of a peak resulting from hydroxyl groups, “B” is the area of a peak resulting from methylene groups, and “C” is the area of a peak resulting from carbonyl groups). The present invention also provides an ink composition for gravure printing or flexography that contains the chlorinated polyolefin resin, a printed material obtained using the above composition, and a printing method using the above composition.

Abstract: A lactide-functionalized polymer is represented by the following formula: wherein R is a hydrogen atom or a methyl group, and wherein R? is a phenyl group or C(O)OR?, wherein R? is an alkyl group having one or more carbon atoms.

Abstract: There is provided a polymerizable composition comprising a compound (A) having a repeating unit having a perfluoropolyether structure and 4 or more polymerizable groups and represented by the specific general formula; an antireflection film comprising a transparent support having thereon at least one low refractive index layer, wherein the low refractive index layer is formed of the polymerizable composition; a polarizing plate comprising a polarization film and two protective films protecting the both surfaces of the polarization film, wherein at least one of the protective films is the antireflection film; an image display device comprising a display, and the antireflection film or the polarizing plate on the outermost surface of the display; and a water-repellent or oil-repellent film formed of the polymerizable composition.

Abstract: A method for preparing a coupled polymer, the method comprising the steps of: (i) polymerizing monomers to form a reactive polymer, and (ii) reacting the reactive polymer with a glycidic ester.

Abstract: A catalyst system obtainable by contacting: A) a metal complex of formula (I) B) an iron complex of the general formula (II) C) an alumoxane or a compound capable of forming an alkyl cation with complexes of formula (I) and (II); Wherein the variables are described in the description.

Abstract: The invention pertains to a low viscosity curable (per)fluoroelastomer [fluoroelastomer (A)] having a number-averaged molecular weight of 3 000 to 45 000, said (per)fluoroelastomer comprising at least 1% moles, with respect to the total moles of recurring units, of recurring units derived from at least one (per)fluoromethoxyalkylvinylether of formula (I): CFX??CX?OCF2ORf??formula (I) wherein X? and X?, equal to or different from each other, are independently H or F; and Rf is selected from the group consisting of C1-C6 (per)fluoroalkyls, linear or branched; C5-C6 cyclic (per)fluoroalkyls; and C2-C6 (per)fluorooxyalkyls, linear or branched, comprising from 1 to 3 catenary ethereal oxygen atoms [monomer (M)].

Abstract: The present invention concerns a method for preparing a polymer comprising a step of radical polymerization of monomers comprising at least monomers (M1) chosen from acrylic acid, one of the salts of same, or the mixture thereof, in which said radical polymerization step is carried out: continuously; at a pH which remains between 3 and 5 during the polymerization step; in the presence of a metabisulfite/persulfate redox pair, for example the sodium metabisulfite/sodium persulfate pair, as a radical initiator, with a metabisulfite/persulfate molar ratio of between 1 and 3.5 and an initiator/monomer molar percentage of between 5% and 18%.